학술논문
Turning the tables on surgical oncology: the aC/ Pancho trial unplugged
Document Type
Clinical report
Author
Source
European Surgery. Dec, 2008, Vol. 40 Issue 6, p277, 7 p.
Subject
Language
English
ISSN
1682-8631
Abstract
BACKGROUND: In esophageal cancer patients neoadjuvant therapy failed to demonstrate a clear benefit in overall survival. A significant advantage can be seen in patients with complete pathological response. METHODS: This review summarizes the results of retrospective clinical studies suggesting p53 as a predictive marker for chemotherapy response. To advance these findings to level of evidence I the aC/ Pancho trial was initiated. RESULTS: The aC/ Pancho trial represents the first prospective randomized trial testing the interaction between p53 and response to chemotherapy. The special design of the aC/ Pancho trial (interaction design), the sample size considerations, the study endpoints and the 12 months accrual of this nationwide study are reported. CONCLUSIONS: The aC/ Pancho trial evaluates for the first time whether the p53 genotype is qualified to select patients who will respond to certain chemotherapy and to guide cancer therapy.